Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission

December 11, 2019 updated by: New Discovery LLC

Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine With the Omission of Immune Globulin to Prevent Hepatitis B Transmission in Mother With High Viral Load: A Multi-Center, Prospective, Randomized and Open-Label Study

Immunoprophylaxis with two hepatitis B vaccinations following the hepatitis B immune globulin (HBIg) and hepatitis B vaccine at birth is largely effective in protecting infants from hepatitis B virus (HBV) infection. However, hepatitis B infection due to immunoprophylaxis failure often occurs in approximately 10% of infants who are born to highly viremic mothers with HBeAg-positive. Maternal HBV DNA > 200,000 IU/mL is the major independent risk for mother-to-child transmission (MTCT). A recent randomized controlled trial has shown that Tenofovir Disoproxil Fumarate (TDF) use during the third trimester of pregnancy could safely reduce the rate of MTCT with few adverse effects when combined with the administration of the standard immunoprophylaxis to the infants. However, HBIg is expensive and not available in many developing countries, resulting approximately 30% of infant infection when they received only HBV vaccination. The present study aims to investigate if highly viremic mothers who are treated with TDF from the second trimester to delivery in combination of infant's standard series of HBV vaccinations (omission of HBIg) have a comparable MTCT rates, when compared to those of mothers who receive TDF at the third trimester in combination of infant's standard HBV vaccinations and a birth dose of HBIg.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a multicenter, prospective, randomized, open-label and parallel two arm study starting from week 14-16 of pregnancy to post-partum week 28. The enrollment from approximately 7 centers will be in blocks for sample balance. By using the randomized table, 280 HBeAg-positive pregnant women with chronic hepatitis B (CHB) will be randomized in a 1:1 ratio in to two arms. Group assignments will be also stratified by the maternal HBV DNA levels >9 log10 versus ≤ 9 log10 IU/mL.

Group A: This is the experimental group. Participating mothers will receive TDF (oral 300 mg tablet daily) starting at gestational weeks 14-16 and continue until delivery. The mothers will be followed together with their infants until postpartum week 28. Infants will receive hepatitis B vaccine at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24. HBIg will be omitted for the infants in this group. However, the birth dose of HBIg will be provided to infants born to mothers who have poor control of maternal viremia (i.e. the levels of HBV DNA >200,000 IU/mL before delivery). Group B: This is the comparative group. Participating mothers will receive TDF (oral 300 mg tablet daily) starting at gestational weeks 28 and continue until delivery. Patients in group B will have similar follow-up schedules as those in the experimental group. Infants will receive hepatitis B vaccine plus HBIg at birth (within 12 hours) and additional hepatitis B vaccine at the age of week 4 and week 24.

Study Type

Interventional

Enrollment (Anticipated)

280

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100069
        • Recruiting
        • Beijing Youan Hospital, Capital Medical University
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hua Zhang, MD
        • Sub-Investigator:
          • Zhongping Duan, MD
    • Chongqing
      • Chongqing, Chongqing, China, 400038
        • Recruiting
        • Southwest Hospital
        • Principal Investigator:
          • Yuming Wang, MD
        • Sub-Investigator:
          • Yangsu Tu, MD
        • Contact:
        • Contact:
    • Guangdong
      • Guangzhou, Guangdong, China, 510623
        • Recruiting
        • Guangzhou Women and Children's Medical Center, Guangzhou Medical University
        • Contact:
        • Contact:
        • Principal Investigator:
          • Thomas Q Zheng, MD
        • Sub-Investigator:
          • Ping He, MD
    • Hebei
      • Shijiazhuang, Hebei, China, 050021
        • Recruiting
        • The Fifth Hospital of Shijiazhuang
        • Contact:
        • Contact:
        • Principal Investigator:
          • Erhei Dai, MD
        • Sub-Investigator:
          • Suwen Li, MD
      • Shijiazhuang, Hebei, China, 050051
        • Recruiting
        • Shijiazhuang Maternal and Child Health Care Hospital
        • Contact:
        • Contact:
        • Principal Investigator:
          • Zhongfu Mo, MD
        • Sub-Investigator:
          • Cuili Yang, MD
    • Shaanxi
      • Xi'an, Shaanxi, China, 710061
        • Recruiting
        • Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Tianyan Chen, MD
        • Principal Investigator:
          • Yingren Zhao, MD
    • Shenzhen
      • Shenzhen, Shenzhen, China, 518112
        • Recruiting
        • The Third People's Hospital of Shenzhen
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yingxia Liu, MD
        • Sub-Investigator:
          • Liuqing Yang, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • HBeAg-positive CHB mothers
  • Age of 20-35 years old
  • Serum HBV DNA levels > 200,000 IU/mL
  • Gestational age between 12-14 weeks.
  • Both mother and father of the child have the ability to understand and are willing to consent to the study.

Exclusion Criteria:

  • Co-infection with (HIV)-1, or hepatitis A, C, D, E or sexual transmitted diseases (STD)
  • History of abortion or congenital malformation in a prior pregnancy
  • Treatment experience (except when antivirals were used for MTCT prevention in a previous pregnancy and discontinued >6 months prior to the current pregnancy)
  • History of renal dysfunction; evidence of liver cancer or decompensation
  • Estimated creatinine clearance (CLCr) <100 mL/min (using the Cockcroft-Gault method based on serum creatinine and ideal body weight)
  • Hypo-phosphoremia; hemoglobin <8 g/dL; neutrophil count <1,000//μL; alanine aminotransferase >5 times upper limit of the normal; total bilirubin >2 mg/dL; albumin <25gm/L;
  • Clinical signs of threatened miscarriage
  • Ultrasonographic evidence of fetal deformity
  • Concurrent treatment with nephrotoxic drugs, steroids, cytotoxic drugs, nonsteroidal anti-inflammatory drugs, or immune modulators;
  • Recipient of solid organ or bone marrow transplant
  • Significant renal, cardiovascular, pulmonary, neurological disease or other health conditions in the opinion of the investigator
  • Fetus's biological father had CHB infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A
This is the experimental group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 14-16 and continue until delivery. The mothers will be followed together with their infants until postpartum week 28. Infants will receive hepatitis B vaccine at birth and additional hepatitis B (HBV) vaccine at the age of week 4 and week 24. HBIg will be omitted for the infants in this group.
Drug: Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.
All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.
Other Names:
  • HBIg 200 IU im for infants in the group B
  • HBV vaccine 10 ug im for all infants
Active Comparator: Group B
This is the comparative group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 28 and continue until delivery. Patients in group B will have similar follow-up schedules as those in the experimental group. Infants will receive hepatitis B vaccine plus HBIg at birth and additional hepatitis B vaccine at the age of week 4 and week 24.
Drug: Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.
All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.
Other Names:
  • HBIg 200 IU im for infants in the group B
  • HBV vaccine 10 ug im for all infants

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment on the proportion of infants who are infected with hepatitis B at the age of 28 weeks in the two groups
Time Frame: From the date of birth to age of 28 weeks.
Compare MTCT rates between the two study groups and demonstrate non-inferiority in efficacy. MTCT rate is defined as the proportion of infants with serum HBV DNA >20 IU/mL and/or HBsAg positivity at 28 weeks of age.
From the date of birth to age of 28 weeks.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment on congenital defects and/or malformation rates in each infant group for comparison
Time Frame: From the date of birth to age of 28 weeks.
Congenital defects and/or malformation rates are defined as the proportion of infants with the aforementioned abnormalities discovered during the study period.
From the date of birth to age of 28 weeks.
Assessment on the reduction of maternal HBV DNA levels at delivery
Time Frame: From the date of randomization until delivery.
Assess the reduction of maternal HBV DNA levels at delivery when compared to the baseline before initiating TDF.
From the date of randomization until delivery.
Maternal serological outcomes during the study: Percentage of mothers who loss/seroconversion of HBsAg or/and HBeAg during the study
Time Frame: From the date of randomization until postpartum week 28.
Assess the percentage of mothers who loss/seroconversion of HBsAg or/and HBeAg during the study.
From the date of randomization until postpartum week 28.
Adverse events of both mothers and infants
Time Frame: From the date of screening until postpartum week 28.
Assess the percentage of mothers or infants who have adverse events during the study.
From the date of screening until postpartum week 28.
Tolerability of TDF therapy: Percentage of mothers who discontinue on TDF therapy due to the adverse event(s) during the study
Time Frame: From the date of randomization until delivery.
Assess the percentage of mothers who discontinue on TDF therapy due to the adverse event(s) during the study.
From the date of randomization until delivery.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

New Discovery LLC

Investigators

  • Study Chair: Calvin Q Pan, MD, Leading Principle Investigator, NYU Langone Health, NYU School of Medicine, NY
  • Study Director: Erhei Dai, MD, The Fifth Hospital of Shijiazhuang, Shijiazhuang, Hebei Province, China

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 10, 2018

Primary Completion (Anticipated)

May 1, 2021

Study Completion (Anticipated)

May 1, 2024

Study Registration Dates

First Submitted

March 18, 2018

First Submitted That Met QC Criteria

March 22, 2018

First Posted (Actual)

March 23, 2018

Study Record Updates

Last Update Posted (Actual)

December 12, 2019

Last Update Submitted That Met QC Criteria

December 11, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • US-G10-P616
  • (2018) 462 No: HGRSL20180412 (Other Identifier: Ministry of Science and Technology of China, HGRM Office)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Viremia

Clinical Trials on Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe